Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Tryptamine Therapeutics ( (AU:TYP) ) just unveiled an announcement.
Tryptamine Therapeutics Limited announced a change in the director’s interest notice, involving the lapse of 4,500,000 Director AGM24 Options. These options were unable to meet the vesting conditions as of December 31, 2024. This change reflects the company’s ongoing management of its securities and could have implications for investor perceptions of the company’s governance practices.
More about Tryptamine Therapeutics
Tryptamine Therapeutics Limited operates in the pharmaceutical industry, focusing on the development and commercialization of innovative therapeutic solutions. The company is committed to advancing medical treatment options, particularly in the realm of mental health.
YTD Price Performance: -7.50%
Average Trading Volume: 4,025,654
Technical Sentiment Consensus Rating: Hold
Current Market Cap: A$47.23M
See more insights into TYP stock on TipRanks’ Stock Analysis page.
